Corporate Information
XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies. XOMA's exceptionally broad technology platform, leading scientific expertise, and fully integrated product development infrastructure, extends from antibody discovery to regulatory approval. A proven development partner and technology licensor, XOMA receives royalties from UCB, S.A. for CIMZIA® (certolizumab pegol). Our pipeline includes an expanding number of proprietary products and collaborative programs at various stages of clinical and preclinical development.
Access XOMA 2009 Proxy Materials
Recent News
Nov 19, 2009
XOMA Receives NASDAQ Determination Letter
Nov 17, 2009
XOMA Appoints Jim Neal Vice President of Business DevelopmentEvents
Nov 18, 2009
6th Annual Lazard Healthcare Conference
$0.05
